Lonza’s Ibex Design offering aims to take Genmab’s candidates from gene to IND in 12 months and then move to reserved manufacturing capacity in Ibex Develop for clinical manufacturing and BLA submission. The agreement aims to provide Genmab with security of supply and to enable Genmab to move rapidly into clinical manufacturing with the flexibility needed to manage an extensive pipeline through the demands of clinical trials.
The new agreement will cover development and clinical manufacturing of drug substance and drug product for certain programs in Genmab’s preclinical and clinical pipeline. These include more complex molecular formats developed using Genmab’s DuoBody technology.
Genmab and Lonza have a longstanding relationship, having worked together on multiple antibody-based programs since 2002.
Karen Fallen, head of Mammalian and Microbial Development and Manufacturing, Lonza Pharma & Biotech, said, “Extending this trusted relationship with Genmab is a great motivation for our teams who have been working together for a number of years. Genmab’s extensive pipeline is an opportunity for us to combine the speed and flexibility of our Ibex Solutions with the know-how needed to manufacture pioneering molecular formats.”